Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 144, Issue PB, 2014, Pages 50-55

  Petit Topin, I ^a,b   Fay, M ^a,b   Resche Rigon, M ^c   Ulmann, A ^c   Gainer, E ^c   Rafestin Oblin, M E ^a,b   Fagart, J ^a,b,c,d,e  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Laboratoire HRA Pharma   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antagonist; Crystal structure; Nuclear receptor; Progesterone receptor; Reproduction; Selectivity; Steroids

Indexed keywords

ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; ULIPRISTAL;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; ION EXCHANGE CHROMATOGRAPHY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR RECOGNITION; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

RUMEX;

EID: 84921526370     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.08.008     Document Type: Article

References (59)

1. M.J. Tsai, and B.W. O'Malley Molecular mechanisms of action of steroid/thyroid receptor superfamily members Annu. Rev. Biochem. 63 1994 451 486
2. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon The nuclear receptor superfamily: the second decade Cell 83 6 1995 835 839
3. M.E. Rafestin-Oblin, B. Couette, C. Radanyi, M. Lombes, and E.E. Baulieu Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation J. Biol. Chem. 264 16 1989 9304 9309
4. S.A. Hild, J.R. Reel, L.H. Hoffman, and R.P. Blye CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits Hum. Reprod. 15 4 2000 822 829
5. J. Jiang, R.F. Wu, Z.H. Wang, H.C. Sun, Z. Xu, and H.M. Xiu Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro Fertil. Steril. 77 5 2002 995 1000
6. M.D. Passaro, J. Piquion, N. Mullen, D. Sutherland, S. Zhai, W.D. Figg, R. Blye, and L.K. Nieman Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women Hum. Reprod. 18 9 2003 1820 1827
7. J. Attardi, and S.A. Burgenson In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone J. Steroid. Biochem. Mol. Biol. 88 3 2000 277 288
8. N. Narvekar, S. Cameron, H.O. Critchley, S. Lin, L. Cheng, and D.T. Baird Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor J. Clin. Endocrinol. Metab. 89 5 2004 2491 2497
9. N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I.M. Spitz Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications Hum. Reprod. Update 11 3 2005 293 307
10. M. Brazert, M.P. Korman, and L.A. Pawelczyk Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology Ginekol Pol. 84 9 2013 794 800
11. J.M. Larner, J.R. Reel, and R.P. Blye Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration Hum. Reprod. 15 5 2000 1100 1106
12. B. Kauppi, C. Jakob, M. Farnegardh, J. Yang, H. Ahola, M. Alarcon, K. Calles, O. Engstrom, J. Harlan, S. Muchmore, A.K. Ramqvist, S. Thorell, L. Ohman, J. Greer, J.A. Carlstedt-Duke, and M. Carlquist The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism J. Biol. Chem. 278 25 2003 22748 22754 Epub 22003 Apr 22749
13. J. Fagart, J.M. Wurtz, A. Souque, C. Hellal-Levy, D. Moras, and M.E. Rafestin-Oblin Antagonism in the human mineralocorticoid receptor EMBO J. 17 12 1998 3317 3325
14. C. Hellal-Levy, B. Couette, J. Fagart, A. Souque, C. Gomez-Sanchez, and M. Rafestin-Oblin Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors FEBS Lett. 464 1-2 1999 9 13
15. I. Petit-Topin, N. Turque, J. Fagart, M. Fay, A. Ulmann, E. Gainer, and M.E. Rafestin-Oblin Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins Mol. Pharmacol. 75 6 2009 1317 1324
16. J. Fagart, A. Hillisch, J. Huyet, L. Barfacker, M. Fay, U. Pleiss, E. Pook, S. Schafer, M.E. Rafestin-Oblin, and P. Kolkhof A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule J. Biol. Chem. 285 39 2010 29932 29940
17. J. Fagart, J. Huyet, G.M. Pinon, M. Rochel, C. Mayer, and M.E. Rafestin-Oblin Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension Nat. Struct. Mol. Biol. 12 6 2005 554 555
18. W. Kabsch Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Cryst. 26 1993 795 800
19. L.C. Storoni, A.J. McCoy, and R.J. Read Likelihood-enhanced fast rotation functions Acta Crystallogr. D Biol. Crystallogr. 60 Pt 3 2004 432 438
20. K.P. Madauss, E.T. Grygielko, S.J. Deng, A.C. Sulpizio, T.B. Stanley, C. Wu, S.A. Short, S.K. Thompson, E.L. Stewart, N.J. Laping, S.P. Williams, and J.D. Bray A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator Mol. Endocrinol. 21 5 2007 1066 1081
21. A.T. Brunger, P.D. Adams, G.M. Clore, W.L. DeLano, P. Gros, R.W. Grosse-Kunstleve, J.S. Jiang, J. Kuszewski, M. Nilges, N.S. Pannu, R.J. Read, L.M. Rice, T. Simonson, and G.L. Warren Crystallography & NMR system: a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54 Pt 5 1998 905 921
22. R.A. Laskowski, M.W. MacArthur, D.S. Moss, and J.M. Thorntorn PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26 1993 283 291
23. P.M. Matias, P. Donner, R. Coelho, M. Thomaz, C. Peixoto, S. Macedo, N. Otto, S. Joschko, P. Scholz, A. Wegg, S. Basler, M. Schafer, U. Egner, and M.A. Carrondo Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations J. Biol. Chem. 275 34 2000 26164 26171
24. J. Huyet, G.M. Pinon, M.R. Fay, J. Fagart, and M.E. Rafestin-Oblin Structural basis of spirolactone recognition by the mineralocorticoid receptor Mol. Pharmacol. 72 2007 563 571
25. B. Eswar, M.S. Marti-Renom, D. Madhusudhan, M.Y. Eramian, U. Shen, and A. Sali Comparative protein structure modeling using modeller Curr. Protoc. Bioinformatics. Chapter 5 Unit 5.6 2006
26. D.P. Edwards The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors J. Mammary Gland Biol. Neoplasia. 5 3 2000 307 324
27. D. Moras, and H. Gronemeyer The nuclear receptor ligand-binding domain: structure and function Curr. Opin. Cell Biol. 10 3 1998 384 391
28. S.P. Williams, and P.B. Sigler Atomic structure of progesterone complexed with its receptor Nature 393 6683 1998 392 396
29. H.C. Raaijmakers, J.E. Versteegh, and J.C. Uitdehaag The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation J. Biol. Chem. 284 29 2009 19572 19579
30. B. He, J.A. Kemppainen, and E.M. Wilson FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor J. Biol. Chem. 275 30 2000 22986 22994
31. J.S. Sack, K.F. Kish, C. Wang, R.M. Attar, S.E. Kiefer, Y. An, G.Y. Wu, J.E. Scheffler, M.E. Salvati, S.R. Krystek Jr., R. Weinmann, and H.M. Einspahr Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone Proc. Natl. Acad. Sci. U. S. A. 98 9 2001 4904 4909
32. P.M. Matias, M.A. Carrondo, R. Coelho, M. Thomaz, X.Y. Zhao, A. Wegg, K. Crusius, U. Egner, and P. Donner Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer J. Med. Chem. 45 7 2002 1439 1446
33. R.T. He, A.T. Kole, T.B. Hnat, G. Stanley, E.L. An, R.I. Stewart, J.T. Kalman, and E.M. Wilson Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance Mol. Cell 16 3 2000 425 438
34. E. Hur, S.J. Pfaff, E.S. Payne, H. Gron, B.M. Buehrer, and R.J. Fletterick Recognition and accommodation at the androgen receptor coactivator binding interface PLoS Biol. 2 9 2004 E274
35. R.K. Bledsoe, K.P. Madauss, J.A. Holt, C.J. Apolito, M.H. Lambert, K.H. Pearce, T.B. Stanley, E.L. Stewart, R.P. Trump, T.M. Willson, and S.P. Williams Ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor J. Biol. Chem. 280 35 2005 31283 31293
36. C.E. Bohl, W. Gao, D.D. Miller, C.E. Bell, and J.T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U. S. A. 102 17 2005 6201 6206
37. C.E. Bohl, D.D. Miller, J. Chen, C.E. Bell, and J.T. Dalton Structural basis for accommodation of nonsteroidal ligands in the androgen receptor J. Biol. Chem. 280 45 2005 37747 37754
38. E. Estebanez-Perpina, J.M. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J.D. Baxter, B.M. Buehrer, P. Webb, R.J. Fletterick, and R.K. Guy The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor J. Biol. Chem. 280 9 2005 8060 8068
39. Y. Li, K. Suino, J. Daugherty, and H.E. Xu Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor Mol. Cell 19 3 2005 367 380
40. M.E. Salvati, A. Balog, W. Shan, D.D. Wei, D. Pickering, R.M. Attar, J. Geng, C.A. Rizzo, M.M. Gottardis, R. Weinmann, S.R. Krystek, J. Sack, Y. An, and K. Kish Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists Bioorg. Med. Chem. Lett. 15 2 2005 271 276
41. Pereira de Jesus-Tran, P.L. Cote, L. Cantin, J. Blanchet, F. Labrie, and R. Breton Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity Protein. Sci. 15 5 2006 987 999
42. C. Sun, J.A. Robl, T.C. Wang, Y. Huang, J.E. Kuhns, J.A. Lupisella, B.C. Beehler, R. Golla, P.G. Sleph, R. Seethala, A. Fura, S.R. Krystek Jr., Y. An, M.F. Malley, J.S. Sack, M.E. Salvati, G.J. Grover, J. Ostrowski, and L.G. Hamann Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold J. Med. Chem 49 26 2006 7596 7599
43. F. Wang, X.Q. Liu, H. Li, K.N. Liang, J.N. Miner, M. Hong, E.A. Kallel, A. van Oeveren, L. Zhi, and T. Jiang Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226 Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62 Pt 11 2006 1067 1071
44. R.T. Askew, J.L. Stanley, and E.M. Wilson Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone J. Biol. Chem. 282 35 2007 25801 25816
45. C.E. Bohl, Z. Wu, D.D. Miller, C.E. Bell, and J.T. Dalton Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design J. Biol. Chem. 282 18 2007 13648 13655
46. E. Estebanez-Perpina, L.A. Arnold, P. Nguyen, E.D. Rodrigues, E. Mar, R. Bateman, P. Pallai, K.M. Shokat, J.D. Baxter, R.K. Guy, P. Webb, and R.J. Fletterick A surface on the androgen receptor that allosterically regulates coactivator binding Proc. Natl. Acad. Sci. U. S. A. 104 41 2007 16074 16079
47. J. Ostrowski, J.E. Kuhns, J.A. Lupisella, M.C. Manfredi, B.C. Beehler, S.R. Krystek Jr., Y. Bi, C. Sun, R. Seethala, R. Golla, P.G. Sleph, A. Fura, Y. An, K.F. Kish, J.S. Sack, K.A. Mookhtiar, G.J. Grover, and L.G. Hamann Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats Endocrinology 148 1 2007 4 12
48. C.E. Bohl, Z. Wu, J. Chen, M.L. Mohler, J. Yang, D.J. Hwang, S. Mustafa, D.D. Miller, C.E. Bell, and J.T. Dalton Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators Bioorg. Med. Chem. Lett. 18 20 2008 5567 5570
49. A.A. Nirschl, Y. Zou, S.R. Krystek Jr., J.C. Sutton, L.M. Simpkins, J.A. Lupisella, J.E. Kuhns, R. Seethala, R. Golla, P.G. Sleph, B.C. Beehler, G.J. Grover, D. Egan, A. Fura, V.P. Vyas, Y.X. Li, J.S. Sack, K.F. Kish, Y. An, J.A. Bryson, J.Z. Gougoutas, J. DiMarco, R. Zahler, J. Ostrowski, and L.G. Hamann N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation J. Med. Chem. 52 9 2009 2794 2798
50. X.E. Zhou, K.M. Suino-Powell, J. Li, Y. He, J.P. Mackeigan, K. Melcher, E.L. Yong, and H.E. Xu Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor J. Biol. Chem. 285 12 2010 9161 9171
51. P. Axerio-Cilies, N.A. Lack, M.R. Nayana, K.H. Chan, A. Yeung, E. Leblanc, E.S. Guns, P.S. Rennie, and A. Cherkasov Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening J. Med. Chem. 54 18 2011 6197 6205
52. C.B. Duke, A. Jones, C.E. Bohl, J.T. Dalton, and D.D. Miller Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets J. Med. Chem. 54 11 2011 3973 3976
53. N.A. Lack, P. Axerio-Cilies, P. Tavassoli, F.Q. Han, K.H. Chan, C. Feau, E. LeBlanc, E.T. Guns, R.K. Guy, P.S. Rennie, and A. Cherkasov Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening J. Med. Chem. 54 24 2011 8563 8573
54. F. Nique, S. Hebbe, C. Peixoto, D. Annoot, J.M. Lefrancois, E. Duval, L. Michoux, N. Triballeau, J.M. Lemoullec, P. Mollat, M. Thauvin, T. Prange, D. Minet, P. Clement-Lacroix, C. Robin-Jagerschmidt, D. Fleury, D. Guedin, and P. Deprez Discovery of diarylhydantoins as new selective androgen receptor modulators J. Med. Chem. 55 19 2012 8225 8235
55. R.S. Munuganti, E. Leblanc, P. Axerio-Cilies, C. Labriere, K. Frewin, K. Singh, M.D. Hassona, N.A. Lack, H. Li, F. Ban, E. Tomlinson Guns, R. Young, P.S. Rennie, and A. Cherkasov Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives J. Med. Chem. 56 3 2013 1136 1148
56. B. Benhamou, T. Garcia, T. Lerouge, A. Vergezac, D. Gofflo, C. Bigogne, P. Chambon, and H. Gronemeyer A single amino acid that determines the sensitivity of progesterone receptors to RU486 Science 255 5041 1992 206 209
57. N. Warriar, C. Yu, and M.V. Govindan Hormone binding domain of human glucocorticoid receptor. Enhancement of transactivation function by substitution mutants M565R and A573Q J. Biol. Chem. 269 46 1994 29010 29015
58. D.S. Geller, A. Farhi, N. Pinkerton, M. Fradley, M. Moritz, A. Spitzer, G. Meinke, F.T. Tsai, P.B. Sigler, and R.P. Lifton Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy Science 289 5476 2000 119 123
59. G.M. Pinon, J. Fagart, A. Souque, G. Auzou, A. Vandewalle, and M.E. Rafestin-Oblin Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension Mol. Cell Endocrinol. 217 1-2 2004 181 188